Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
10 other companies have their registered office at the same address; threshold 10.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
UCB Ventures from Anderlecht, company number BE0667816096, closed financial year 2025 with a result of € 65.8 million after tax. Compared with financial year 2024, the result moved from € 782,569 to € 65.8 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 20, 2026.
€ 213.8 million
▲ 44% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 65.8 million
▲ € 65 million vs 2024
Profit after tax over the fiscal year.
€ 307,993
▼ 80% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 66.6 million.
People and assets in 2025
2
Average over the fiscal year, from the social balance sheet.
€ 665,283
▼ 50% vs 2024
€ 332,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 52,756
▼ 49% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 85 days on average.
€ 115,798
▲ 53% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Profit after taxes | € -5,780,609 | € -7,548,783 | € 782,569 | € 65,812,318 | ▲ € 65 million |
| Equity | € 39,796,459 | € 32,247,676 | € 148,030,245 | € 213,842,563 | ▲ 44% |
| Total debts | € 41,542,123 | € 52,621,963 | € 179,923 | € 225,036 | ▲ 25% |
| Cash | € 797 | € 30 | € 1,561,113 | € 307,993 | ▼ 80% |
| Retained profit | € -20,203,541 | € -27,752,324 | € 782,569 | € 66,594,887 | ▲ € 65.8 million |
| Bank debt | € 41,368,654 | € 52,317,243 | € 0 | € 0 | |
| Balance sheet total | € 81,467,596 | € 85,039,997 | € 148,543,578 | € 214,507,225 | ▲ 44% |
| Employees (FTE) | 2.7 | 2 | 2 | 2 |
Key figures of UCB Ventures, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to UCB Ventures?
What happened at UCB Ventures in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Alistair HENRY stepped down as director. NBB
- Sandrine DUFOUR stepped down as director. NBB
- Jean-Christophe TELLIER stepped down as director. NBB
- Denelle J. WAYNICK JOHNSON stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 65.8 million (▲ € 65 million vs 2024). Source: NBB ↗
- Alistair HENRY became a director. NBB
- Denelle J. WAYNICK JOHNSON became a director. NBB
- Sandrine DUFOUR became a director. NBB
In short
From € 5.8 million loss in 2022 to € 65.8 million profit in 2025.
Paid € 1,855 in corporate taxes since 2022.
Best year ever: 2025, with € 65.8 million profit.
Pays suppliers within 85 days on average.
Management
The shares are held by UCB SA (100%) and UCB FIPAR SA (0%). It owns 100% of UCB Ventures Belgium, 25% of Rinri Therapeutics Ltd., 17.5% of Vianautis Bio Limited, 16.5% of Switch Therapeutics Inc., 14.8% of Cenos Therapeutics Inc. and 14.3% of SpliceBio S.L. itself.
Directors
According to the 2025 annual accounts
since 2022 · until 2028
Jean-Christophe TELLIER
Chairman of the board
Also active at: UCB PHARMA, UCB Fipar, UCB Ventures Belgium
since 2022 · until 2028
since 2024 · until 2030
since 2023 · until 2028
Shareholders
100%
0%
Participations
100%
Rinri Therapeutics Ltd.
25%
Vianautis Bio Limited
17.5%
Switch Therapeutics Inc.
16.5%
Cenos Therapeutics Inc.
14.8%
SpliceBio S.L.
14.3%
Iris Medicine Inc
12.3%
StrideBio, inc
11.4%
Walden Biosciences Inc.
11.4%
Locanabio Inc.
6.6%
RTW Biotech Opportunities Ltd
6.1%
AVP Early Stage II SLP
3.2%
Code Biotherapeutics Inc.
2.6%
Neurona Therapeutics Inc.
2.4%
Establishments
Establishment units
Physical locations of this company
Researchdreef 60
1070 Anderlecht
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 10 companies are registered at this address.
All companies at this address →UCB Belgium
U C B same network
UCB PHARMA same network
€ 4.6 billion revenue · 2025
UCB Fipar same network
Fondation Emmanuel Janssen
+5 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0667.816.096
- VAT number
- BE 0667.816.096
- Registered office
- Researchdreef 60, 1070 Anderlecht
- Names & denominations
- UCB Ventures
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 19 December 2016
- Peppol
- Not registered
- Activities · NACE
Activiteiten van geldmarkt- en niet-geldmarktbeleggingsfondsen
Beleggingstrusts en -fondsen en vergelijkbare financiële instellingen